ADIPOQ and Glucose intolerance: AdipoRaMab exhibited effects reported for adiponectin (6, 7), i.e., AMPK phosphorylation at C2C12 myotubes, and improved glucose intolerance and insulin resistance in mice with high-fat diet–induced obesity (Figs. 2 and Fig. 3).